When cancer starts in the uterus, it is called uterine cancer. The uterus is the pear-shaped organ in a woman's pelvis (the area below your stomach and in between your hip bones). The uterus, also called the womb, is where the baby grows when a woman is pregnant. The most common type of uterine cancer is also called endometrial cancer because it forms in the lining of your uterus, called the endometrium.
When uterine cancer is found early, treatment is most effective. The most common sign of uterine cancer is bleeding that is not normal for you because of when it happens or how heavy it is. This could mean bleeding, even a little bit, after you have gone through menopause; periods that are longer than seven days; bleeding between periods; or any other bleeding that is longer or heavier than is normal for you.
Other symptoms, such as pain or pressure in your pelvis, also may occur if you have uterine cancer. If you have any of these symptoms, talk to your doctor, nurse, or other health care professional right away. They may be caused by something other than cancer, but the only way to know is to see your health care professional.
Before the osteoporosis drug Evista is approved for breast cancer in the U.S. the Food and Drug Administration (FDA) will take the advice of an advisory panel.
Researchers at the Translational Genomics Research Institute (TGen) today announced the discovery of previously unrecognized alterations in a gene called FGFR2 in a subset of endometrial cancers, the most common gynecologic cancer in the United States.
A study released today at the Society of Gynecologic Oncologists 38th Annual Meeting on Women's Cancer found few patients were aware of genetic cancer syndromes and the high risk of developing cancer if genetic mutations were found. Fewer still were motivated to follow up on this information with their own healthcare provider or genetic counseling/testing services.
Women who donate their eggs for stem cell research or in vitro fertilization are not at increased risk of health complications, and most of the risks are a result of the hormones used to stimulate their bodies to release more than one egg, according to a report commissioned by the California Institute of Regenerative Medicine and released by the Institute of Medicine, Bloomberg reports.
Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies.
According to a new study by researchers in the U.S., oral contraceptives and intrauterine devices (IUD) appear to provide long-term protection against endometrial cancer.
An FDA advisory panel on Wednesday recommended that a warning label be added to tamoxifen, an agency-approved drug for treating and preventing breast cancer, the AP/Seattle Post-Intelligencer reports (Bridges, AP/Seattle Post-Intelligencer, 10/18).
A new study suggests that women with endometrial cancer should be screened for inherited mutations that could lead to a high risk of several other cancers.
According to new research women who take oestrogen-only hormone replacement therapy for 20 years or longer to treat the symptoms of menopause, put themselves at greater risk of developing breast cancer.
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.
Below are comments from Len Lichtenfeld, MD, American Cancer Society deputy chief medical officer, in response to the results of the STAR trial.
According to drug company Lilly it's osteoporosis drug Evista is as effective as Tamoxifen in reducing the risk of breast cancer in high-risk women.
Laparoscopy proves safe, reduces hospital stay, and results in improved quality of life.
According to a new study released this week, women at high risk for breast cancer who take the well-known drug Tamoxifen, can reduce their long-term risk of developing the disease.
Cline said there has been much debate about whether high levels of dietary soy are safe for postmenopausal women. Soy products are sometimes sold as a natural alternative to traditional estrogen therapy, which does increase the risk of endometrial cancer.
"Our study defines a standard of care for this aggressive and growing form of uterine cancer," said Schwartz, who is also assistant chief of obstetrics and gynecology at Yale-New Haven Hospital. The procedure more accurately determines the complete stage and appropriate treatment and reduces the recurrence of the cancer.
Two similar comprehensive literature reviews and an editorial about the varying risk with different postmenopausal hormone therapy regimens have been published this month in Human Reproduction Update.
...and starting a family later in life increases risk of breast cancer and melanoma but reduces the risk of ovarian, cervix and uterine cancer according to an international study conducted by a team from The Queensland Institute of Medical Research (QIMR).
A new study suggests that, after surgery, all colon tumors should be tested to learn if the patient may have an inherited syndrome that carries an extremely high risk of cancer. It also suggests that this prescreening can be done using a relatively inexpensive microscopy test already used in hospital pathology laboratories.
In two studies of African-American women with endometrial cancer, a group of investigators from Walter Reed Army Medical Center and the National Cancer Institute has found that African-American women with advanced endometrial cancer have more aggressive tumors than Caucasian women, potentially leading to worse outcomes.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.